

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT
SUCCESSFUL COMPLETION
OF LONG-TERM HUMAN SAFETY TRIAL OF KT-939

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the **“Company”**, together with its subsidiaries, the **“Group”**) to update its shareholders and potential investors on the latest developments related to the Group.

Reference is made to (i) the voluntary announcement of the Company dated 9 September 2025, in relation to the long-term human safety trial (the **“Long-Term Safety Trial”**) of KT-939, for which enrollment of all subjects was completed in September 2025; and (ii) the voluntary announcement of the Company dated 10 June 2026, in relation to the interim result of the Long-Term Safety Trial, which shows positive interim data.

The board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that the long-term human safety trial of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting melanin production, was successfully completed on 4 September 2026. A total of 114 subjects received continuous administration of KT-939 for 52 consecutive weeks, and preliminary data indicate that none of them experienced any adverse skin reactions, in line with the 28-week interim clinical results, fully demonstrating the excellent safety profile of KT-939.

The Long-Term Safety Trial is an open-label, single-arm, single-center study designed to evaluate the potential for long-term topical use of cosmetics containing the raw material KT-939 to induce adverse skin reactions in humans, with a primary focus on the safety of topical application of 0.2% KT-939 for 52 consecutive weeks.

As a next generation innovative whitening and freckle-removing raw material, KT-939 is subject to registration and approval by the National Medical Products Administration (“NMPA”) prior to market launch. The Long-Term Safety Trial was completed under the guidance of the Methods for Long-Term Human Use Testing for cosmetic raw materials, issued by the NMPA on 18 June 2026, and its results constitute one of the most critical components of the registration application materials for KT-939.

The Company is actively advancing the registration application process, and upon obtaining the Long-Term Safety Trial results, plans to complete the submission of all application materials to the NMPA as soon as practicable.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 7 September 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*